Ultragenyx shares surge as blockbuster hopeful burosumab continues to perform in pivotal study
Just in time for its R&D day today, Ulytragenyx $RARE and its partners at Kyowa Hakko Kirin outlined updated 48 week data on burosumab, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
